YAFO Capital and U.S. Outcome Capital announced a strategic partnership to strengthen global services for biopharmaceutical clients
YAFO Capital and US-based Outcome Capital announced a strategic partnership to strengthen global services for biopharmaceutical clients.
This collaboration will expand and enhance the global strategic and financial advisory services provided by both parties to their life sciences and biopharmaceutical client companies.
(Yafa Capital Establishes Boston Joint Office)
[Boston and Shanghai, September 18, 2023] YAFO Capital and US-based Outcome Capital announced a strategic partnership to strengthen global services for biopharmaceutical clients. Headquartered in Shanghai, YAFO is a boutique investment bank and advisory firm focused on the Chinese and Asian markets, providing global biopharmaceutical companies with services such as BD strategy development, asset transactions, and licensing. Outcome focuses on the US and European markets, offering life sciences and healthcare advisory and investment banking services to help management teams and boards achieve financial and strategic success. This cooperation will enhance and expand the global strategic and financial advisory services that both parties provide to their life sciences and biopharmaceutical clients.
"Boston is the most important biopharmaceutical innovation center in the United States and even globally. We are pleased to announce a deeper collaboration with Outcome, believing that our combined senior deal-making and scientific teams from China and the U.S. will better help our clients unlock the potential of their innovation pipelines and successfully enter Asian and global markets," stated Mr. Jiang Xiaoyang, founder of Yafa Capital, and Mr. Tao Kun, head of U.S. operations.
"Outcome will continue to collaborate with Yafa to expand innovative models, providing clients with more pathways to success in life sciences deals and mergers and acquisitions. China's emergence in the global biotechnology field offers abundant opportunities for China-US cooperation," said Dr. Oded Ben-Joseph, Managing Director of Outcome.
This brand-new collaboration will provide the two companies with a broader global regional coverage, complement a more international business team, promote cross-border transactions, and create greater value for client companies, achieving effective business development and cooperation results on a global scale.
"At Yafa Capital, we have a deep understanding of the tremendous value that Chinese biotechnology companies bring to the global life sciences field. Our strategic cooperation with Outcome further strengthens our commitment to supporting clients' business development, providing them with an extensive network of global licensing partners and broad industry insights," said Mr. Ye Duo, Managing Partner of Yafa Capital and Head of China Business.
"By leveraging Jaffar's investment banking and life sciences resources and capabilities in China and Asia, the collaboration allows us to focus more on our core markets in the US and Western Europe," said Mr. Arnold Freedman, Managing Director of Outcome.
About Jaffa Capital
Yafa Capital was established in 2013 as a new type of investment and investment banking advisory institution, dedicated to investment, financing services, product introduction, and asset incubation for biopharmaceutical projects in China and overseas. Its funds cooperate with pharmaceutical companies for asset investment and mergers and acquisitions, while Yafa Global Healthcare focuses on cross-border and domestic licensing transactions of pharmaceutical products. Based on its extensive global network of contacts and resources, it has successfully promoted a large number of overseas projects into the Chinese market over the past decade and assisted multiple Chinese products in completing overseas licensing. Yafa has an experienced global transaction team covering major pharmaceutical innovation regions including the United States, Japan, and Europe. The core partners are all senior Wall Street investment banking professionals or have experience in multinational pharmaceutical companies, providing strong support for client transactions. Yafa is headquartered in Shanghai, with branches in London, Boston, Los Angeles, Tokyo, Milan, Cambridge, and other locations. It has ranked first in the number of cross-border biopharmaceutical licensing and M&A transactions for three consecutive years.
For more information, please visitwww.yafocapital.com
关于Outcome Capital
Outcome Capital is a unique and highly specialized life sciences consulting and investment banking firm that provides innovative companies with mergers and acquisitions, partnerships, financing, and strategic advisory services. Using an experienced 'strategy-driven execution' approach, it achieves success and value creation by helping management teams and boards navigate financial and strategic markets. Outcome's strength comes from its multidisciplinary team of industry veterans, who draw on extensive scientific, operational, strategic, and transaction expertise from various points along the value chain, as well as a broad industry network and relationships. The team consists of former CEOs, PhD/MD-level scientists and clinicians, business development executives, and seasoned commercialization experts dedicated to advancing lab-originated innovative technologies. Member of the Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
Outcome section completed transaction cases
Media Contact
Jaffa Capital
Xiang Wendi, Vice President
Outcome Capital
Steve Holstein
